Fairmount Funds Management’s Cogent Biosciences COGT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $44.7M | Hold |
6,225,641
| – | – | 5.79% | 10 |
|
|
2025
Q1 | $37.3M | Hold |
6,225,641
| – | – | 5.79% | 9 |
|
|
2024
Q4 | $48.6M | Hold |
6,225,641
| – | – | 4.83% | 10 |
|
|
2024
Q3 | $67.2M | Hold |
6,225,641
| – | – | 5.45% | 10 |
|
|
2024
Q2 | $52.5M | Buy |
6,225,641
+1,500,000
| +32% | +$12.6M | 5.93% | 8 |
|
|
2024
Q1 | $31.8M | Buy |
4,725,641
+1,166,666
| +33% | +$7.84M | 3.46% | 10 |
|
|
2023
Q4 | $20.9M | Hold |
3,558,975
| – | – | 2.21% | 11 |
|
|
2023
Q3 | $34.7M | Hold |
3,558,975
| – | – | 4.17% | 8 |
|
|
2023
Q2 | $42.1M | Buy |
3,558,975
+800,000
| +29% | +$9.47M | 5.94% | 5 |
|
|
2023
Q1 | $29.8M | Hold |
2,758,975
| – | – | 5.12% | 7 |
|
|
2022
Q4 | $31.9M | Hold |
2,758,975
| – | – | 5.06% | 7 |
|
|
2022
Q3 | $41.2M | Hold |
2,758,975
| – | – | 7.24% | 2 |
|
|
2022
Q2 | $24.9M | Buy |
2,758,975
+1,200,000
| +77% | +$10.8M | 5.7% | 8 |
|
|
2022
Q1 | $11.7M | Hold |
1,558,975
| – | – | 2.76% | 15 |
|
|
2021
Q4 | $13.4M | Hold |
1,558,975
| – | – | 4.41% | 9 |
|
|
2021
Q3 | $13.1M | Hold |
1,558,975
| – | – | 4.77% | 9 |
|
|
2021
Q2 | $12.6M | Hold |
1,558,975
| – | – | 5.2% | 8 |
|
|
2021
Q1 | $13.7M | Hold |
1,558,975
| – | – | 5.77% | 9 |
|
|
2020
Q4 | $17.5M | Sell |
1,558,975
-1
| -0% | -$11 | 6.26% | 9 |
|
|
2020
Q3 | $13.7M | Buy |
+1,558,976
| New | +$13.7M | 5.81% | 8 |
|